Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report
Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report
复制标题
卡博替尼对携带 CD74-ROS1 融合的晚期非小细胞肺癌患者的有效治疗：病例报告
DOI：
10.2147/ott.s234733
复制
发表时间：
2020-02
影响因子：
4
通讯作者：
Jianing Jiang
中科院分区：
文献类型：
--
作者：
Gang Wang;Jinqi Gao;Jinyan Lv;Xi Chen;Jinyu Wu;Ruoyu Wang;Jianing Jiang
摘要卡博替尼已被证明在许多实体恶性肿瘤中具有有效的抗ROS 1活性，特别是针对那些在克唑替尼治疗后具有溶剂前沿抗性突变的患者。关于最常见的CD 74-R 0 S1融合，卡博替尼的功效仅在体外得到证实。因此，在本研究中，我们评估了卡博替尼在具有CD 74-R 0 S1融合的晚期非小细胞肺癌（NSCLC）患者中的功效。患者女，40岁，因咳嗽、白色痰、胸痛1个月就诊。胸部CT扫描显示右肺中叶实变伴双肺多发性空洞病变。对右肺中叶病变活检样本的组织学分析提示肺腺癌。在两线化疗和EGFR-TKI治疗后，检测到CD 74-ROS 1重排，患者接受卡博替尼治疗1.5年。由于卡博替尼耐药性的发展，克唑替尼治疗被应用，并证明了临床有效性，直到现在。总之，我们报告了卡博替尼治疗CD 74-ROS 1阳性晚期NSCLC患者的首例有效性。在获得卡博替尼耐药性后，克唑替尼仍然是一种有效的治疗选择。
Abstract Cabozantinib has been shown to have potent anti-ROS1 activity in many solid malignancies, particularly against those with solvent-front resistance mutations following crizotinib therapy. With regard to the most common CD74-ROS1 fusion, the efficacy of cabozantinib has only been demonstrated in vitro. Therefore, we evaluate the efficacy of cabozantinib in a patient with advanced non-small-cell lung cancer (NSCLC) harboring a CD74-ROS1 fusion in the present study. A 40-year-old female patient presented with 1-month history of cough, white sputum and chest pain. Chest CT scan revealed a consolidation in the middle lobe of the right lung together with multiple cavity lesions spreading in both lungs. Histopathological analysis of biopsy samples from the lesion in the middle lobe of the right lung suggested lung adenocarcinoma. After two lines of chemotherapy and EGFR-TKI therapy, a CD74-ROS1 rearrangement was detected and the patient was administered with cabozantinib for 1.5 years. Since cabozantinib resistance developed, crizotinib therapy was applied and demonstrated clinical effectiveness until now. Together, we report the first case of cabozantinib effectiveness in treating a CD74-ROS1-positive advanced NSCLC patient. Crizotinib remained as an effective therapeutic option following the acquisition of cabozantinib resistance.
登录
查看更多内容
影响因子：
--
作者：
Mirela Stancu;T. C. King;A. Maizel
通讯作者：
Mirela Stancu;T. C. King;A. Maizel
DOI：
10.1158/1078-0432.ccr-14-1385
发表时间：
2015-01-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Katayama R;Kobayashi Y;Friboulet L;Lockerman EL;Koike S;Shaw AT;Engelman JA;Fujita N
通讯作者：
Fujita N
DOI：
10.1016/j.jtho.2017.01.004
发表时间：
2017-05
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Lin JJ;Ritterhouse LL;Ali SM;Bailey M;Schrock AB;Gainor JF;Ferris LA;Mino-Kenudson M;Miller VA;Iafrate AJ;Lennerz JK;Shaw AT
通讯作者：
Shaw AT
影响因子：
3.3
作者：
Sozzi, G;Carney, D
通讯作者：
Carney, D
影响因子：
8.4
作者：
G. Sozzi
通讯作者：
G. Sozzi